VMD Stock Analysis: Buy, Sell, or Hold?
VMD - Viemed Healthcare, Inc. Common Shares
$9.17
-0.32 (-3.37%)
▼
5d:
+2.57%
30d:
-4.18%
90d:
+10.75%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
VMD is down 7.5% this week, but smart money is accumulating calls. Top strike: $7.5 2026-06-18 with 10 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When VMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: VMD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: VMD shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$16.63
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$10.33
11.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: VMD is currently trading at $9.17, which is considered oversold relative to its 30-day fair value range of $9.21 to $9.87. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.6) compared to its historical average (14.0). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, VMD is in a strong uptrend. Immediate support is located at $8.34, while resistance sits at $9.94. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+37.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, VMD is in a strong uptrend. Immediate support is located at $8.34, while resistance sits at $9.94. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $13.00 (+37.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$9.21 -
$9.87
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 37.0% below Wall St target ($13.00)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$9.21 -
$9.87
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.51
(5.5%)
Support & Resistance Levels
Support Level
$8.34
Resistance Level
$9.94
Current Trend
Strong Uptrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.56
Wall Street Target
$13.00
(+37.0%)
Revenue Growth (YoY)
27.5%
Profit Margin
5.2%
Valuation Premium vs History
+3.6% premium
PE vs Historical
15.6 vs 14.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$9.83
(+4%)
2-Year Target
$10.19
(+7%)
3-Year Target
$10.55
(+11%)
3-Yr Target (if PE normalizes)
(PE: 16→14)
PE COMPRESSION
$9.50
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 38.6%)
$35.82
(+278%)
Base:
(SPY PE: 15.6, Growth: 38.6%)
$25.29
(+167%)
Bear:
(PE: 13.2, Growth: 38.6%)
$21.49
(+127%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 25.65 | Current EPS (TTM): $0.37
Bull Case
$17.21
(+81%)
Analyst growth 64.9%, PE expands to 28.2
Base Case
$15.65
(+65%)
Market implied 64.9%, PE stable at 25.7
Bear Case
$6.45
(-32%)
Severe decline -20.0%, PE contracts to 21.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 15, 2026 2:38 PM ET
Data refreshes hourly during market hours. Next update: 3:38 PM
Data refreshes hourly during market hours. Next update: 3:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Moore
SELL
65000 shares
2026-03-20
Michael Moore
SELL
40232 shares
2026-03-19
Michael Moore
SELL
31570 shares
2026-03-18
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$84 | 66 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$392 | 58 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 64 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 59 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 55 HOLD |
